What happened to GW Pharmaceuticals?
Jazz Pharmaceuticals (NASDAQ:JAZZ) has officially closed its $7.2B acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH). With the acquisition, Jazz gains access to GW’s cannabinoid portfolio, including Epidiolex, which raked in $510.5M in sales in 2020. …
What does GW Pharmaceuticals make?
GW is the global leader in developing cannabinoid-based medicines. GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics.
What is GW drug?
GW Pharmaceuticals is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country.
Where is GW Pharmaceuticals located?
GW Pharmaceuticals is a biopharmaceutical company that develops and markets cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant….Overview Suggest Edit.
| Type | Public | |
|---|---|---|
| Founded | 1998 | |
| HQ | Cambridge, GB | Map |
| Website | gwpharm.com | |
| Employee Ratings | 3.6 | More |
1 autre ligne
Who bought GW Pharma?
Jazz Pharmaceuticals
DUBLIN , /PRNewswire/ — Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) (« GW »), a leader in the science, development and commercialization of cannabinoid-based prescription medicines.
Who bought Greenwich Pharmaceuticals?
Jazz Pharmaceuticals
Greenwich Biosciences, now a part of Jazz Pharmaceuticals, is the U.S. leader in the field of cannabinoid prescription medicines.
Who bought GW Pharmaceuticals?
Jazz Pharmaceuticals
In the first marijuana industry buyout of 2021, Jazz Pharmaceuticals (NASDAQ:JAZZ) agreed to pay a hefty $7.6 billion to acquire GW Pharmaceuticals (NASDAQ:GWPH), a developer of cannabis-based medications.
Who owns Jazz Pharmaceuticals?
Bruce C. Cozadd
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a biopharmaceutical company based in Ireland. It was founded in 2003….Jazz Pharmaceuticals.
| Type | Public company |
|---|---|
| Headquarters | Waterloo Exchange, Waterloo Road, D04 E5W7, Dublin, Ireland |
| Area served | Worldwide |
| Key people | Bruce C. Cozadd (Chairman & CEO) |
14 autres lignes
Who owns GW Pharmaceuticals?
Jazz Pharmaceuticals
GW Pharmaceuticals/Organisations mères
What is the stock price of GW Pharmaceuticals?
Key Turning Points
| 52-Week High | 219.57 |
|---|---|
| Last Price | 218.96 |
| Fibonacci 61.8% | 168.95 |
| Fibonacci 50% | 153.32 |
| Fibonacci 38.2% | 137.68 |
1 autre ligne
Who are gwgw pharmaceuticals?
- GW Pharmaceuticals is now part of Jazz Pharmaceuticals. GW is the global leader in developing cannabinoid-based medicines. GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics.
When did Jazz Pharmaceuticals acquire GW Pharmaceuticals plc?
- Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation
What is GW Pharmaceuticals' stock price and ticker symbol?
- What is GW Pharmaceuticals‘ stock symbol? GW Pharmaceuticals trades on the NASDAQ under the ticker symbol « GWPH. » What is GW Pharmaceuticals‘ stock price today? One share of GWPH stock can currently be purchased for approximately $218.96.
Should you hold GW Pharmaceuticals (gwph) stock?
- The consensus among Wall Street research analysts is that investors should « hold » GW Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GWPH, but not buy additional shares or sell existing shares.
